even if the company raised a little money, this will run on positive news relating to their technologies. The market is more receptive to these companys now. I had a look at their web site and i would like to see news on their vaccines program as it potentially could totally rerate the stock. Vaccines are a hot topic at the moment and SLT is capped at bugger all. You guys are spot on with the selll side, i have never seen this stock so thin and a run off this chart could be really good to watch. do some research. This was on their website.
Project 4 - Vaccines for hepatitis E and hepatitis A
This technology has already been covered effectively in the description of Project 1. Essentially, the development of the technology in Project 1 may lead to an opportunity to sell that technology to vaccine manufacturers for use in vaccine production, as opposed to diagnostic kit production. In the case of hepatitis E, a license would need to be sought from Genelabs Technologies, Inc., the owner of the patent over the hepatitis E genome, or from GlaxoSmithKline to whom Genelabs Technologies, Inc. have granted an exclusive world license, but this situation may change pending results of clinical trials.
Add to My Watchlist
What is My Watchlist?